Ringers in Dextrose (ringer's and 5% dextrose injection)

Rinvoq (upadacitinib extended-release tablets)

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Skyrizi (risankizumab-rzaa injection)

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Risperdal (risperidone)

Risperdal (risperidone) is an atypical antipsychotic prescribed to treat:

Risperdal Consta (risperidone)

Risperdal Consta (risperidone) is an antipsychotic-type psychiatric medication used to treat certain mental/mood disorders (schizophrenia, bipolar disorder).

Rykindo (risperidone)

Rykindo (risperidone) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

Uzedy (risperidone)

Uzedy (risperidone) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.

Rituxan (rituximab)

Rituxan (rituximab) is a cancer medication used in combination with other cancer medicines to treat non-Hodgkin's lymphoma. Rituxan is also used in combination with another drug called methotrexate to treat symptoms of adult rheumatoid arthritis.

Rituxan Hycela (rituximab and hyaluronidase human injection)

Rituxan Hycela (rituximab and hyaluronidase human) injection is a combination of a CD20-directed cytolytic antibody and an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Chronic Lymphocytic Leukemia (CLL).

Truxima (rituximab-abbs injection)

Truxima (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with non-Hodgkin's lymphoma (NHL): relapsed or refractory, low grade or follicular, CD20-positive B- cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; and non-progressing (including stable disease), low-grade, CD20-positive, B- cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.